BioMEMS and Biomedical Nanotechnology. Questo articolo non è disponibile.BioMEMS and Biomedical Nanotechnology

Less than twenty years ago photolithography and medicine were total strangers to one another. They had not yet met, and not even looking each other up in the classi?eds. And then, nucleic acid chips, micro?uidics and microarrays entered the scene, and rapidly these strangers became indispensable partners in biomedicine. Asrecentlyastenyearsagothenotionofapplyingnanotechnologytothe?ghtagainstd- ease was dominantly the province of the ?ction writers. Thoughts of nanoparticle-vehicled deliveryoftherapeuticalstodiseasedsiteswereanexerciseinscienti?csolitude,andgrounds for questioning one's ability to think "like an established scientist". And today we have nanoparticulate paclitaxel as the prime option against metastatic breast cancer, proteomic pro?lingdiagnostictoolsbasedontargetsurfacenanotexturing,nanoparticlecontrastagents for all radiological modalities, nanotechnologies embedded in high-distribution laboratory equipment, and no less than 152 novel nanomedical entities in the regulatory pipeline in the US alone. Thisisatransformingimpact,byanymeasure,withclearevidenceoffurtheracceleration, supported by very vigorous investments by the public and private sectors throughout the world. Even joining the dots in a most conservative, linear fashion, it is easy to envision scenarios of personalized medicine such as the following: patient-speci?c prevention supplanting gross, faceless intervention strategies; early detection protocols identifying signs of developing disease at the time when the disease is most easily subdued; personally tailored intervention strategies that are so routinely and inexpensively realized, that access to them can be secured by everyone; technologies allowing for long lives in the company of disease, as good neighbors, without impairment of the quality of life itself.

Rashid Bashir completed his Ph.D. in 1992. From Oct 1992 to Oct 1998, he worked at National Semiconductor in the Process Technology Development Group as Sr. Engineering Manager. He is currently a Professor of Electrical and Computer Engineering and Courtesy Professor of Biomedical Engineering at Purdue University. He has authored or coauthored over 100 journal and conference papers, has over 25 patents, and has given over 30 invited talks. His research interests include biomedical microelectromechanical systems, applications of semiconductor fabrication to biomedical engineering, advanced semiconductor fabrication techniques, and nano-biotechnology. In 2000, he received the NSF Career Award for his work in Biosensors and BioMEMS. He also received the Joel and Spira Outstanding Teaching award from School of ECE at Purdue University, and the Technology Translation Award from the 2001 BioMEMS and Nanobiotechnology World Congress Meeting in Columbus, OH. He was also selected by National Academy of Engineering to attend the Frontiers in Engineering Workshop in Fall 2003. https://engineering.purdue.edu/LIBNA

Professor Wereley completed his masters and doctoral research at Northwestern University and joined the Purdue University faculty in August of 1999 after a two-year postdoctoral appointment at the University of California Santa Barbara in the Department of Mechanical and Environmental Engineering. At UCSB he focused exclusively on developing diagnostic techniques for microscale systems, work which ultimately led to developing, patenting, and licensing to TSI, Inc., the micro-Particle Image Velocimetry technique. His current research interests include designing and testing microfluidic MEMS devices, investigating biological flows at the cellular level, improving micro-scale laminar mixing, and developing new micro/nano flow diagnostic techniques. Professor Wereley has co-authored Fundamentals and Applications of Microfluidics, Artech House, 2002.

Professor Mauro Ferrari is a pioneer in the fields of bioMEMS and biomedical nanotechnology. As a leading academic, a dedicated entrepreneur, and a vision setter for the Nation's premier Federal programs in nanomedicine, he brings a three-fold vantage perspective to his roles as Editor-in-Chief for this work. Dr. Ferrari has authored or co-authored over 150 scientific publications, 6 books, and over 20 US and

International patents. Dr. Ferrari is also Editor-in-Chief of Biomedical Microdevices and series editor of the new Springer series on Emerging Biomedical Technologies.

Several private sector companies originated from his laboratories at the Ohio State University and the University of California at Berkeley over the years. On a Federal assignment as Special

Expert in Nanotechnology and Eminent Scholar, he has provided the scientific leadership for the development of the Alliance for Cancer Nanotechnology of the National Cancer Institute, the world-largest medical nanotechnology operation to date. Dr. Ferrari trained in mathematical physics in Italy, obtained his Master's and Ph.D. in Mechanical

Engineering at Berkeley, attended medical school at The Ohio State University, and served in faculty positions in Materials Science and Engineering, and Civil and Environmental Engineering in Berkeley, where he was first tenured. At Ohio State he currently serves as Professor of Internal Medicine, Division of Hematology and Oncology, as Edgar Hendrickson Professor of Biomedical Engineering, and as Professor of Mechanical Engineering. He is Associate Director of the Dorothy M. Davis

Heart and Lung Research Institute, and the University's Associate Vice President for Health Science, Technology and Commercialization.